SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Patel Manesh R)) conttype:(refereed)
 

Sökning: (WFRF:(Patel Manesh R)) conttype:(refereed) > Ticagrelor versus C...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005641naa a2200769 4500
001oai:lup.lub.lu.se:6b3b1873-d506-41ee-bb11-40100c077fff
003SwePub
008230831s2017 | |||||||||||000 ||eng|
009oai:DiVA.org:uu-334966
009oai:prod.swepub.kib.ki.se:134885761
0247 a https://lup.lub.lu.se/record/6b3b1873-d506-41ee-bb11-40100c077fff2 URI
0247 a https://doi.org/10.1056/NEJMoa16116882 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3349662 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1348857612 URI
040 a (SwePub)lud (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Hiatt, William Ru University of Colorado4 aut
2451 0a Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
264 1c 2017
500 a Martin Björck (Uppsala Universitet, Institutionen för kirurgiska vetenskaper, kärlkirurgi) var National Lead Investigator för den svenska delen av studien och en av dessa ”Investigators”
520 a BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.METHODS: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months.RESULTS: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49).CONCLUSIONS: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a Adenosine/adverse effects
653 a Aged
653 a Cardiovascular Diseases/mortality
653 a Clopidogrel
653 a Double-Blind Method
653 a Female
653 a Hemorrhage/chemically induced
653 a Humans
653 a Intermittent Claudication/drug therapy
653 a Ischemia/drug therapy
653 a Kaplan-Meier Estimate
653 a Leg/blood supply
653 a Male
653 a Middle Aged
653 a Peripheral Arterial Disease/drug therapy
653 a Platelet Aggregation Inhibitors/adverse effects
653 a Purinergic P2Y Receptor Antagonists/therapeutic use
653 a Ticagrelor
653 a Ticlopidine/adverse effects
7001 a Fowkes, F Gerry Ru University of Edinburgh4 aut
7001 a Heizer, Gretchenu Duke University4 aut
7001 a Berger, Jeffrey Su New York University4 aut
7001 a Baumgartner, Irisu University of Bern4 aut
7001 a Held, Peteru AstraZeneca, Sweden4 aut
7001 a Katona, Brian Gu AstraZeneca, US4 aut
7001 a Mahaffey, Kenneth Wu Stanford University4 aut
7001 a Norgren, Larsu Örebro University4 aut
7001 a Jones, W Schuyleru Duke University4 aut
7001 a Blomster, Juuso4 aut
7001 a Millegård, Marcus4 aut
7001 a Reist, Craig4 aut
7001 a Patel, Manesh R4 aut
7001 a Gottsäter, Andersu Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups4 cre0 (Swepub:lu)medf-ago
7102 a University of Coloradob University of Edinburgh4 org
7102 a EUCLID Trial Steering Committee and Investigators
7730 t The New England journal of medicineg 376, s. 32-40q 376<32-40x 0028-4793x 1533-4406
8564 u http://dx.doi.org/10.1056/NEJMoa1611688y FULLTEXT
8564 8u https://lup.lub.lu.se/record/6b3b1873-d506-41ee-bb11-40100c077fff
8564 8u https://doi.org/10.1056/NEJMoa1611688
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-334966
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:134885761

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy